GRF Grifols, S.A.
Debt Financing ·
Grifols says it refinanced all of its 2027 maturities with an upsized Term Loan B of about €3 billion equivalent and lifted its revolving credit commitment to over $2 billion. Net leverage was 4.2x at the end of June.
We have not published a story on Grifols yet. When there is news, it will appear here.
Grifols, S.A. is a vertically integrated global producer of plasma derivatives, and the company says it ranks among the three largest producers in the industry by total sales. Its activities include sourcing raw material through a plasma collection network of more than 400 operating centers in the United States, Germany, Austria, the Czech Republic, Hungary, Canada and Egypt, manufacturing plasma derivative products, and selling them to healthcare providers. The company also researches, develops, manufactures and markets in vitro diagnostics products, including analytical instruments, reagents and software for clinical and blood bank laboratories, along with hospital products. Among its recent milestones, the European Medicines Agency certified the entire value chain of Grifols Egypt in December 2025, and the company acquired 28 plasma collection centers in the United States from ImmunoTek in February 2025. Its San Diego plant began manufacturing Grifols DG Gel card and reagent red blood cells, used for blood typing, in October 2025. Through its acquisition of Biotest Holdings, Grifols has increased its shareholding in the German company Biotest, which supplies plasma protein products and biotherapeutic drugs, to 100.0% of ordinary voting shares.
| Product or program | What it is | Stage |
|---|---|---|
| Plasma-derived medicines | Plasma derivative products, including immunoglobulins, albumin and coagulation factors | |
| Grifols DG Gel card and reagent red blood cells | Blood typing products used to ensure transfusion compatibility | manufacturing started October 2025 at San Diego plant |
| In vitro diagnostics products | Analytical instruments, reagents and software for clinical and blood bank laboratories |
Grifols, S.A. trades under the ticker GRF on BME.
Grifols, S.A. is listed on BME. Our directory also records these other listings: BME:GRF.P; DUS:OZTA; EUROTLX:4GRF; FWB:OZTA; GETTEX:G0F0; GETTEX:OZTA; HAM:OZTA; HAN:OZTA; LS:A2ABUQ; LSIN:0RDU; LSIN:0RDV; LSX:A2ABUQ; LSX:A2ABZN; MUN:OZTA; NASDAQ:GRFS; OTC:GIFLF; OTC:GIFOF; SWB:OZTA; TRADEGATE:OZTA; VIE:GRF; XETR:OZTA.
The SEC Central Index Key (CIK) for Grifols, S.A. is 1438569. Its filings are on SEC EDGAR.
Our directory records Grifols, S.A. under Spain.
Our directory classifies Grifols, S.A. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Grifols, S.A. is ES0171996087.
aibio.space lists Grifols, S.A. among 2,820 public biotech companies and publishes its news here as stories appear.
Grifols, S.A. is a vertically integrated global producer of plasma derivatives, and the company says it ranks among the three largest producers in the industry by total sales. Its activities include sourcing raw material through a plasma collection network of more than 400 operating centers in the United States, Germany, Austria, the Czech Republic, Hungary, Canada and Egypt, manufacturing plasma derivative products, and selling them to healthcare providers.
Plasma-derived medicines: Plasma derivative products, including immunoglobulins, albumin and coagulation factors
Grifols DG Gel card and reagent red blood cells: Blood typing products used to ensure transfusion compatibility Stage: manufacturing started October 2025 at San Diego plant.
Our latest story on Grifols, dated Jul 28, 2026: "Grifols refinances all 2027 maturities with about €3 billion term loan". Grifols says it refinanced all of its 2027 maturities with an upsized Term Loan B of about €3 billion equivalent and lifted its revolving credit commitment to over $2 billion. Net leverage was 4.2x at the end of June. Source.
Our latest debt story, dated Jul 28, 2026: "Grifols refinances all 2027 maturities with about €3 billion term loan". Grifols says it refinanced all of its 2027 maturities with an upsized Term Loan B of about €3 billion equivalent and lifted its revolving credit commitment to over $2 billion. Net leverage was 4.2x at the end of June. Source.
SEC records list Grifols, S.A.'s filer category as: Large accelerated filer.
SEC records list its business address as 1585 BROADWAY, NEW YORK, NY, 10036.
Its most recent filing in our record is a 6-K filed 2026-07-30. All of its filings are on SEC EDGAR. Source.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio